| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/05/2001 | WO2001047914A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047897A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | WO2001047879A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | WO2001047561A1 Hyaluronic acid in the treatment of cancer |
| 07/05/2001 | WO2001047559A1 Patches for external use |
| 07/05/2001 | WO2001047557A1 Oral preparations for diabetes |
| 07/05/2001 | WO2001047556A1 Composition promoting lacrimal secretion |
| 07/05/2001 | WO2001047543A2 Activation and inhibition of the immune system |
| 07/05/2001 | WO2001047533A2 INHIBITION OF GSK-3$g(b) |
| 07/05/2001 | WO2001047519A1 Powdery biotin preparations |
| 07/05/2001 | WO2001047514A1 Use of hypoglycemic agent for treating impaired glucose metabolism |
| 07/05/2001 | WO2001047513A1 Treatment of hyperproliferative disorders |
| 07/05/2001 | WO2001047511A2 Treatment of drug-resistant human immunodeficiency virus infection |
| 07/05/2001 | WO2001047510A2 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 07/05/2001 | WO2001047509A2 Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions |
| 07/05/2001 | WO2001047508A2 Combination of trimebutine with an opioid analgesic |
| 07/05/2001 | WO2001047507A2 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
| 07/05/2001 | WO2001047490A1 Devices for the delivery of drugs having antiprogestinic properties |
| 07/05/2001 | WO2001047420A1 Electromagnetic object detector provided with an additional electrode and intended for a medical radiation apparatus |
| 07/05/2001 | WO2001047354A1 Model animal with favorite onset of rheumatoid arthritis |
| 07/05/2001 | WO2001003720A9 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 07/05/2001 | WO2001000822A3 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 07/05/2001 | WO2001000184A3 Combination of mtp inhibitors and lipid reducers and the use thereof in medicaments |
| 07/05/2001 | WO2000076552A8 Methods and compositions for control of bone formation via modulation of leptin activity |
| 07/05/2001 | WO2000073348A3 Methods and compositions for inhibiting neoplastic cell growth |
| 07/05/2001 | WO2000069896A3 Molecular interactions in haematopoietic cells |
| 07/05/2001 | WO2000066138A3 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue |
| 07/05/2001 | WO2000059942A3 Human obesity protein binding protrein-2 homolog and uses thereof |
| 07/05/2001 | WO2000034483A9 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 07/05/2001 | WO1999064045A9 Novel therapeutic agents for membrane transporters |
| 07/05/2001 | WO1999053910A8 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 07/05/2001 | US20010007022 An antibody which binds procalcitonin but not free calcitonin, free katacalcin and free N-procalcitonin; used as an in vitro or in vivo diagnostic agent |
| 07/05/2001 | US20010007019 Useful in methods for the induction of bone, cartilage and tissue formation, growth and development of the endometrium and in the acceleration of wound healing |
| 07/05/2001 | US20010006980 Administering to a mammal an EP4 receptor subtype agonist, e.g., prostaglandins PGE1 and PGE2; also may include an active bisphosphonate; bone disorders; osteoporosis; Paget's disease; rhumatoid arthritis; hypercalcemia of malignancies |
| 07/05/2001 | US20010006974 Combination therapy for lymphoproliferative diseases |
| 07/05/2001 | US20010006971 Administering an antiallergen of loratadine or metabolite of loratadine, desloratadine; migraines, stroke, orthostatic hypotension, gastrointestinal stasis, nausea, dizziness and jet lag; also psychological disorders; 5-HT7 receptors |
| 07/05/2001 | US20010006967 Administering an analgesic amount of tramadol and an amount of an excitatory opioid receptor antagonist, e.g naltrexone, nalone, to lessen the antianalgesia, hyperalgesia, hyper-excitability, physical dependence and or tolerance |
| 07/05/2001 | US20010006944 Treating noninvasive fungus-induced rhinosinusitis by mucoadministering an antifungal agent; culturing noninvasive fungus from a mammalian mucus sample for antigen/antibody production; apparatus for collecting nasal mucus |
| 07/05/2001 | US20010006799 Histidine kinase polypeptides |
| 07/05/2001 | US20010006798 Novel FtsL |
| 07/05/2001 | US20010006790 Ihhibition of amylin release |
| 07/05/2001 | US20010006662 A lipid regulating agent selected from a fibrate or statin dispersed or dissolved in a hydrophilic, amorphous polymer in which antilipidimic agent present as metastable, amorphous phase |
| 07/05/2001 | US20010006649 Stable oral pharmaceutical dosage forms |
| 07/05/2001 | US20010006640 Compounds and methods to inhibit or augment an inflammatory response |
| 07/05/2001 | US20010006635 Decreasing localized inflammatory responses in a tissue of a patient by administering to said patient heparinase enzyme in an effective amount sufficient to decrease said localized inflammatory response |
| 07/05/2001 | DE19960924A1 Amphiphile Polyamine, deren Anwendungen und Verfahren zu ihrer Synthese Amphiphilic polyamines, their applications and methods for their synthesis |
| 07/05/2001 | CA2396693A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | CA2395993A1 Antidiabetic preparation for oral administration |
| 07/05/2001 | CA2395663A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | CA2395544A1 Method of achieving persistent transgene expression |
| 07/05/2001 | CA2395524A1 Chemotherapeutant screening method |
| 07/05/2001 | CA2395430A1 Treatment of drug-resistant human immunodeficiency virus infection |
| 07/05/2001 | CA2395335A1 Genes identified as required for proliferation of e. coli |
| 07/05/2001 | CA2395284A1 Inhibition of gsk-3.beta. |
| 07/05/2001 | CA2395276A1 Identification of novel splice variants of the human catalytic subunit c.beta. of camp-dependent protein kinase and the use thereof |
| 07/05/2001 | CA2395242A1 Composition for inhibiting macrophage activity |
| 07/05/2001 | CA2395236A1 Basolateral sorting signal and inhibitors thereof |
| 07/05/2001 | CA2395173A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | CA2394944A1 Combinations of a receptor tyrosine kinase inhibitor with an organic compound capable of binding to .alpha.1-acidic glycoprotein |
| 07/05/2001 | CA2394880A1 Activation and inhibition of the immune system |
| 07/05/2001 | CA2394747A1 Use of trimebutine for treating pain |
| 07/05/2001 | CA2394745A1 Combination of trimebutine with an opioid analgesic |
| 07/05/2001 | CA2394727A1 Pyrimidine and triazine kinase inhibitors |
| 07/04/2001 | EP1113015A1 Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists |
| 07/04/2001 | EP1112741A1 Use of protease inhibitors for the treatment of necrotizing infections |
| 07/04/2001 | EP1112738A2 Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| 07/04/2001 | EP1112497A1 Ykl-40 as a marker and prognostic indicator for cancers |
| 07/04/2001 | EP1112381A1 Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
| 07/04/2001 | EP1112368A1 Use of protein kinase kiaa0551 as pharmaceutical |
| 07/04/2001 | EP1112363A1 Metabotropic gaba receptor complex issued from the central nervous system |
| 07/04/2001 | EP1112361A2 Promotion or inhibition of angiogenesis and cardiovascularization |
| 07/04/2001 | EP1112356A1 Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancers |
| 07/04/2001 | EP1112286A1 Secreted proteins and polynucleotides encoding them |
| 07/04/2001 | EP1112252A1 Kappa agonist compounds and pharmaceutical formulations thereof |
| 07/04/2001 | EP1112250A1 Therapeutic compounds and methods |
| 07/04/2001 | EP1112106A2 Serotonergic 5ht2 agonists for treating glaucoma |
| 07/04/2001 | EP1112095A1 Biologically active implants |
| 07/04/2001 | EP1112090A2 Method of stimulating prosaposin receptor activity |
| 07/04/2001 | EP1112088A1 Method for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor |
| 07/04/2001 | EP1112083A2 Use of an angiogenic factor for the treatment of microvascular angiopathies |
| 07/04/2001 | EP1112078A2 New use |
| 07/04/2001 | EP1112075A1 Compositions for the treatment of male erectile dysfunction |
| 07/04/2001 | EP1112074A1 Taurolidine and/or taurultam against infectious ulcer or gastritis |
| 07/04/2001 | EP1112071A1 Growth hormone secretagogues |
| 07/04/2001 | EP1112068A2 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors |
| 07/04/2001 | EP1112067A2 Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes |
| 07/04/2001 | EP1112063A1 Lipstatin derivative-soluble fiber tablets |
| 07/04/2001 | EP1112061A1 Drug preparations for treating sexual dysfunction |
| 07/04/2001 | EP0896538B1 Use of activity inhibiting dipeptidyl peptidase iv effectors for lowering the blood glucose level in mammals |
| 07/04/2001 | EP0789586B1 Compounds for the prevention and treatment of helminth infections |
| 07/04/2001 | CN1302215A Local preparation containing poloxamer and other microbe killing agent and applicator |
| 07/04/2001 | CN1302207A Combined therapy for bipolar disorders |
| 07/04/2001 | CN1302201A Ophthalmic compositions containing galactomannan polymers and borate |
| 07/04/2001 | CN1301534A Stable slow-releasing oral administration composition |
| 07/03/2001 | US6255471 CRFG-1b, a target and marker for chronic renal failure |
| 07/03/2001 | US6255468 MPROT12 polynucleotides and methods thereof |
| 07/03/2001 | US6255456 Enzymatic polypeptide; for use in diagnosis, detection, prevention and treatment of cancer and immune defects |
| 07/03/2001 | US6255338 Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors |
| 07/03/2001 | US6255334 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
| 07/03/2001 | US6255329 Combined use of pramipexole and sertraline for the treatment of depression |